SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

SAN

100.72

+1.15%↑

EI

250.8

-5.75%↓

SHL.DE

48.09

-2.89%↓

ARGX

545.4

+3.57%↑

FRE

39.69

+2.21%↑

Search

Laboratorios Farmaceuticos Rovi SA

Aperta

SettoreSettore sanitario

51.25 0.79

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

50.15

Massimo

51.45

Metriche Chiave

By Trading Economics

Entrata

-57M

32M

Vendite

199M

434M

P/E

Media del settore

19.288

63.778

EPS

0.457

Rendimento da dividendi

2.11

Margine di Profitto

7.411

Dipendenti

2,197

EBITDA

40M

138M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+43.34% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.11%

2.39%

Utili prossimi

7 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-770M

2.6B

Apertura precedente

50.46

Chiusura precedente

51.25

Notizie sul Sentiment di mercato

By Acuity

25%

75%

66 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bearish Evidence

Laboratorios Farmaceuticos Rovi SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

2 apr 2025, 23:55 UTC

Azioni calde

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 apr 2025, 22:50 UTC

I principali Market Mover

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 apr 2025, 21:08 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 apr 2025, 21:00 UTC

Utili

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 apr 2025, 23:56 UTC

Discorsi di Mercato

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:44 UTC

Discorsi di Mercato

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 apr 2025, 23:44 UTC

Notizie principali

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 23:32 UTC

Discorsi di Mercato

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

2 apr 2025, 23:12 UTC

Discorsi di Mercato

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 apr 2025, 23:10 UTC

Discorsi di Mercato

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 apr 2025, 23:09 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:57 UTC

Discorsi di Mercato

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 apr 2025, 22:56 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 22:56 UTC

Discorsi di Mercato

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 apr 2025, 22:43 UTC

Notizie principali
Acquisizioni, Fusioni, Takeovers

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 apr 2025, 22:12 UTC

Discorsi di Mercato

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 apr 2025, 21:48 UTC

Notizie principali

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 apr 2025, 21:41 UTC

Discorsi di Mercato

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

2 apr 2025, 21:17 UTC

Discorsi di Mercato

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 apr 2025, 21:04 UTC

Notizie principali

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 apr 2025, 21:03 UTC

Discorsi di Mercato

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 apr 2025, 20:53 UTC

Utili

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 apr 2025, 20:52 UTC

Utili

Kaiser Aluminum Changes Inventory Acctg Methodology

Confronto tra pari

Modifica del prezzo

Laboratorios Farmaceuticos Rovi SA Previsione

Obiettivo di Prezzo

By TipRanks

43.34% in crescita

Previsioni per 12 mesi

Media 73.75 EUR  43.34%

Alto 82 EUR

Basso 65.5 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Laboratorios Farmaceuticos Rovi SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

51.4 / 52.35Supporto e resistenza

A breve termine

Weak Bearish Evidence

A termine intermedio

Neutral Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

66 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.